0 CHECKOUT

High-Grade Glioma - Pipeline Review, H1 2015

  • ID: 3293100
  • May 2015
  • 118 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AngioChem Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cavion LLC
  • GlaxoSmithKline plc
  • Oncolytics Biotech Inc.
  • MORE

High-Grade Glioma - Pipeline Review, H1 2015

Summary

This, ‘High-Grade Glioma - Pipeline Review, H1 2015’, provides an overview of the High-Grade Glioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AngioChem Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cavion LLC
  • GlaxoSmithKline plc
  • Oncolytics Biotech Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
High-Grade Glioma Overview
Therapeutics Development
Pipeline Products for High-Grade Glioma - Overview
Pipeline Products for High-Grade Glioma - Comparative Analysis
High-Grade Glioma - Therapeutics under Development by Companies
High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes
High-Grade Glioma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
High-Grade Glioma - Products under Development by Companies
High-Grade Glioma - Products under Investigation by Universities/Institutes
High-Grade Glioma - Companies Involved in Therapeutics Development
AngioChem Inc.
Bayer AG
Boehringer Ingelheim GmbH
Cavion LLC
GlaxoSmithKline plc
Kinex Pharmaceuticals, LLC
Millennium Pharmaceuticals, Inc.
Oncolytics Biotech Inc.
Sanofi
Stemline Therapeutics, Inc.
Targepeutics, Inc.
Tocagen Inc.
Virttu Biologics Limited
High-Grade Glioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANG-1005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
crenolanib besylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Gliomas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GB-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSV-1716 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KX-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mibefradil dihydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pelareorep - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plerixafor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sorafenib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Glioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TBX-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Toca-Gamma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Toca-RNAi - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vocimagene amiretrorepvec + flucytosine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
High-Grade Glioma - Recent Pipeline Updates
High-Grade Glioma - Dormant Projects
High-Grade Glioma - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for High-Grade Glioma, H1 2015
Number of Products under Development for High-Grade Glioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
High-Grade Glioma - Pipeline by AngioChem Inc., H1 2015
High-Grade Glioma - Pipeline by Bayer AG, H1 2015
High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2015
High-Grade Glioma - Pipeline by Cavion LLC, H1 2015
High-Grade Glioma - Pipeline by GlaxoSmithKline plc, H1 2015
High-Grade Glioma - Pipeline by Kinex Pharmaceuticals, LLC, H1 2015
High-Grade Glioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
High-Grade Glioma - Pipeline by Oncolytics Biotech Inc., H1 2015
High-Grade Glioma - Pipeline by Sanofi, H1 2015
High-Grade Glioma - Pipeline by Stemline Therapeutics, Inc., H1 2015
High-Grade Glioma - Pipeline by Targepeutics, Inc., H1 2015
High-Grade Glioma - Pipeline by Tocagen Inc., H1 2015
High-Grade Glioma - Pipeline by Virttu Biologics Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
High-Grade Glioma Therapeutics - Recent Pipeline Updates, H1 2015
High-Grade Glioma - Dormant Projects, H1 2015
High-Grade Glioma - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for High-Grade Glioma, H1 2015
Number of Products under Development for High-Grade Glioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

AngioChem Inc.
Bayer AG
Boehringer Ingelheim GmbH
Cavion LLC
GlaxoSmithKline plc
Kinex Pharmaceuticals, LLC
Millennium Pharmaceuticals, Inc.
Oncolytics Biotech Inc.
Sanofi
Stemline Therapeutics, Inc.
Targepeutics, Inc.
Tocagen Inc.
Virttu Biologics Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Qiagen N.V.
  • Elekta AB
  • Roche Diagnostics Ltd.
  • Bristol-Myers Squibb
  • Genentech, Inc.